Jeevan Patra | Drug Design | Best Researcher Award

Best Researcher Award

Jeevan Patra
National Institute of Technology, Rourkela

Jeevan Patra
Affiliation National Institute of Technology, Rourkela
Country India
Scholar ID n3bgLpAAAAAJ
Documents 35
Citations 323
h-index 6
Subject Area Drug Design
Event Global Academic Awards
ORCID 0000-0002-2709-4268

Jeevan Patra, a researcher affiliated with the National Institute of Technology, Rourkela, India. The profile summarizes publicly available academic indicators, research specialization, scholarly contributions, publication performance, and recognition within the field of Drug Design. The article follows a neutral, encyclopedia-inspired presentation intended for academic recognition and reference.[1]

Abstract

Jeevan Patra has developed research interests centered on Drug Design and associated interdisciplinary biomedical sciences. Available scholarly indicators demonstrate sustained publication activity supported by peer-reviewed research outputs and measurable citation impact. The profile illustrates an active contribution to scientific literature and highlights engagement with contemporary pharmaceutical and molecular research topics.[1][2]

Keywords

Drug Design, Computational Drug Discovery, Medicinal Chemistry, Pharmaceutical Research, Molecular Modeling, Bioinformatics, Chemical Biology, Structure-Based Drug Design, Academic Research, Scientific Publications.

Introduction

Drug Design represents an essential research discipline supporting the discovery and optimization of therapeutic compounds through experimental and computational methodologies. Researchers working in this area contribute to advances in medicinal chemistry, molecular pharmacology, and pharmaceutical development. Academic performance is commonly evaluated through publication records, citation metrics, collaboration networks, and contributions to innovation.[3]

Research Profile

Jeevan Patra is affiliated with the National Institute of Technology, Rourkela, India. Publicly available scholarly metrics indicate approximately 35 indexed research documents with more than 323 citations and an h-index of 6. These indicators reflect continued participation in scholarly publishing and ongoing contributions to research related to Drug Design and associated biomedical disciplines.[1]

Research Contributions

The available publication record demonstrates involvement in multidisciplinary investigations supporting pharmaceutical innovation, computational chemistry, molecular interactions, and drug discovery strategies. Research contributions emphasize scientific rigor, peer-reviewed dissemination, and collaboration across complementary scientific domains.[2]

  • Drug discovery methodologies.
  • Medicinal chemistry research.
  • Computational molecular analysis.
  • Scientific collaboration and publication.

Publications

The research portfolio consists of peer-reviewed journal publications indexed by major scholarly databases. Publications collectively demonstrate continuing academic engagement in pharmaceutical sciences and computational approaches for therapeutic development.[2]

  • Approximately 35 scholarly publications.
  • Citation count exceeding 323.
  • Research indexed within recognized academic databases.

Research Impact

Citation metrics and publication activity indicate measurable scholarly visibility within the Drug Design research community. Citation-based indicators, together with publication consistency, suggest that the research has contributed to ongoing scientific discussions and knowledge development in pharmaceutical sciences.[1]

Award Suitability

Based on publicly available scholarly indicators, Jeevan Patra demonstrates characteristics commonly considered during academic recognition processes, including peer-reviewed publications, citation performance, research productivity, and contributions within the field of Drug Design. Final award decisions remain dependent upon the formal evaluation criteria established by the Global Academic Awards and supporting documentation submitted by the nominee.[4]

Conclusion

The academic profile presented here summarizes available bibliometric information together with an overview of scholarly activities in Drug Design. Through peer-reviewed publications, citation performance, and institutional affiliation, the profile reflects sustained participation in scientific research while providing an objective reference suitable for academic recognition documentation.[1]

References

  1. Google Scholar. (n.d.). Scholar profile: Jeevan Patra.
    https://scholar.google.com/citations?user=n3bgLpAAAAAJ&hl=en
  2. Crossref DOI Foundation. (n.d.). Digital Object Identifier System.
    https://doi.org/10.1038/nrd.2017.203
  3. Computational Design of Pyrazole Derivatives for Management of Autoimmune Disease. https://link.springer.com/chapter/10.1007/978-3-032-12320-6_8
  4. Global Academic Awards. (n.d.). Award nomination information.
    https://globalacademicawards.com/

Ulises Martinez Ortega | Medicinal Chemistry | Young Scientist Award

Dr. Ulises Martinez Ortega | Medicinal Chemistry | Young Scientist Award

Professor | National Autonomous University of Mexico | Mexico

Dr. Ulises Martinez-Ortega’s research focuses on computational chemistry, molecular modeling, and drug design, particularly targeting cancer-related pathways such as EGFR inhibition. With 3 publications, 11 citations across 11 documents, and an h-index of 2, his work contributes to the development of quinazoline-based compounds with therapeutic potential. He applies advanced computational techniques, including free energy calculations, to optimize molecular interactions. His research supports the discovery of efficient, targeted treatments and advances understanding in medicinal chemistry and pharmaceutical development.

Citation Metrics (Scopus)

12

10

8

6

4

2

0

Citations
11

Documents
3

h-index
2

        🟦 Citations    🟥 Documents    🟩 h-index


View Scopus Profile
View ORCID Profile
View Google Scholar Profile

Featured Publications

Alchemical Free Energy-Based Optimization of Quinazoline Derivatives as Potent EGFR Inhibitors with Cytotoxic Activity
– Bioorganic and Medicinal Chemistry, 2025

Computational Design and Evaluation of Quinazoline-Based Compounds for Targeted Cancer Therapy
– Medicinal Chemistry Research

Molecular Modeling and Drug Design Approaches for EGFR Inhibitors in Cancer Treatment
– Journal of Molecular Modeling

Mohammad Sadegh Taghizadeh | Drug Discovery | Best Researcher Award

Dr. Mohammad Sadegh Taghizadeh | Drug Discovery | Best Researcher Award

Shiraz University | Iran

Dr. Mohammad Sadegh Taghizadeh is a highly accomplished researcher at the Institute of Biotechnology, whose work centers on bioactive peptides, protein hydrolysates, structure-based drug design, encapsulation, and natural product research. His research integrates experimental biology, molecular docking, and dynamic simulation to uncover new therapeutic agents and improve bioavailability in peptide-based drug delivery systems. He has made significant contributions to understanding peptide–receptor interactions, anticancer bioactives, and sustainable biotechnological production, with influential publications in prestigious journals such as PLOS One, Scientific Reports, npj Science of Food, and Critical Reviews in Biotechnology. His innovative studies on cyclotide ligands, oral delivery systems, and plant-based bioactive compounds have advanced the fields of pharmaceutical biotechnology and functional food science, earning him strong citation impact and scholarly recognition. In addition to his research, Dr. Mohammad Sadegh Taghizadeh has served as a keynote speaker and workshop lecturer, contributing to scientific capacity-building in molecular biology, computational modeling, and peptide biochemistry, reflecting his leadership and excellence in modern biotechnology research.

Profile: Google Scholar

Featured Publications

  • Taghizadeh, M. S., Niazi, A., Moghadam, A., & Afsharifar, A. (2022). Experimental, molecular docking and molecular dynamic studies of natural products targeting overexpressed receptors in breast cancer. PLOS ONE, 17(5), e0267961.

  • Mirzapour-Kouhdasht, A., McClements, D. J., Taghizadeh, M. S., Niazi, A., & others. (2023). Strategies for oral delivery of bioactive peptides with focus on debittering and masking. npj Science of Food, 7(1), 22.

  • Mirzapour-Kouhdasht, A., Sabzipour, F., Taghizadeh, M. S., & others. (2019). Physicochemical, rheological, and molecular characterization of colloidal gelatin produced from common carp by-products using microwave and ultrasound-assisted extraction. Journal of Texture Studies, 50(5), 416–425.

  • Taghizadeh, M. S., Retzl, B., Muratspahić, E., Trenk, C., Casanova, E., & Gruber, C. W. (2022). Discovery of the cyclotide caripe 11 as a ligand of the cholecystokinin-2 receptor. Scientific Reports, 12(1), 9215.

  • Shahraki, Z., Taghizadeh, M. S., Niazi, A., Rowshan, V., & Moghadam, A. (2024). Enhancing bioactive compound production in Salvia mirzayanii through elicitor application: Insights from in vitro and in silico studies. Food Bioscience, 60, 104185.